Stevanato Group Reports Strong Q1, Reaffirms 2026 Guidance Amidst Biologics Demand

summarizeSummary

Stevanato Group reported strong first-quarter 2026 financial results, with revenue up 10% and Adjusted EBITDA up 14%, driven by its Biopharmaceutical and Diagnostic Solutions segment. The company reaffirmed its full-year guidance despite ongoing weakness in its Engineering segment, and is adapting operations to meet high demand for biologics cartridges.

check_boxKey Events

• Strong Q1 Financial Performance

  Reported 10% revenue growth (constant currency) to €273.6 million and a 14% increase in Adjusted EBITDA to €65.5 million, with Adjusted diluted EPS growing 10% to €0.11.

• Full-Year Guidance Reaffirmed

  Maintained 2026 guidance for revenue (€1.260B-€1.290B), Adjusted EBITDA (€331.8M-€346.9M), and Adjusted diluted EPS (€0.59-€0.63).

• Biopharmaceutical & Diagnostic Solutions (BDS) Drives Growth

  BDS segment revenue increased 13% (16% constant currency), with high-value solutions growing 17% and GLP1s accounting for 21-22% of total revenue.

• Engineering Segment Faces Headwinds

  Engineering segment revenue declined 31% due to slow new order intake, though operational optimization efforts are yielding initial margin improvements.

auto_awesomeAnalysis

This filing provides the detailed transcript of the Q1 2026 earnings call, elaborating on the financial results and guidance previously announced on May 7. The company demonstrated robust growth in its core Biopharmaceutical and Diagnostic Solutions segment, fueled by high-value solutions and significant demand from GLP1 therapies. While the Engineering segment continues to face challenges with order intake, management highlighted initial margin improvements from optimization efforts and strategic adaptations, such as converting a vial production line to meet surging cartridge demand. Maintaining full-year guidance despite mixed segment performance indicates management's confidence in its strategic direction and operational flexibility.